MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Tracy Klein, PhD, FNP; Phil Levin, PhD; William Origer, MD; Rich Clark, MD, MPH; Walter Hardin, DO, MBA

Members Present by Phone: Caryn Mickelson, PharmD; Kelley Burnett, DO; Dave Pass, MD; Jim Slater, PharmD

Staff Present: Richard Holsapple, RPh; Roger Citron, RPh; Trevor Douglass, DC, MPH; Sarah Servid, PharmD; Lindsay Newton; Kim Wentz, MD; Julia Verhulst, PharmD; Jonnaliz Corbett; Megan Herink, PharmD

Staff Present by Phone: Dean Haxby, PharmD; Kathy Sentena, PharmD

Audience: *Maria Agapova, Teva Pharmaceuticals; *Donna Thurston, Celgene, Inc.; Leslie Mann, Celgene, Inc.; Cheryl Fletcher, AbbVie; *Margaret Olman, AbbVie; Deron Grothe, Teva; Leo Yasinski, Merck; Anthony Hager, BMS; *Barbara Perry, Pfizer; Michael Estoos, Pfizer; Nina Hartman, Neurocrin; Raulo Frear, Merck; Peirce Enjerson, OHSU; Sean Pascoe, Novartis; *Lisa Stroup, Neurocrine; *Sylvia Churchill, Amgen; Camille Kerr, Amgen; Lisa Boyle, WVP Health; Bruce Smith, Glaxo Smith Kline; Andrew Seaman, Central City Concern; Martyna Witkowska, Central City Concern; Jennifer Svec, MedImpact; Sher Adams, Sunovion; Jeana Colabianchi, Sunovion; *Bethany Jones, Sunovion; Lyle Laird, Sunovion; Venus Holder, Lilly

(*) Provided verbal testimony

Written testimony provided:

I. CALL TO ORDER
A. The meeting was called to order at approximately 1:02 pm. Introductions were made by Committee members and staff.
B. Mr. Douglass discussed the roles and responsibilities of the P&T Committee.
C. Mr. Douglass discussed the new conflict of interest form and the requirements that each committee member fill it out and declare any new conflicts by contacting him.
D. The committee elected Tracy Klein as the chair and Caryn Mickelson as the vice chair.
E. Mr. Douglass provided a department update and legislative update.
F. Approval of agenda and November minutes presented by Mr. Citron. (pages 4-8)

**ACTION:** Motion to approve, 2nd, All in Favor.

### II. CONSENT AGENDA TOPICS

A. Noctiva (desmopressin) abbreviated drug review (page 9)
   1. Restrict use for OHP-funded conditions through Prior Authorization.

**ACTION:** Motion to approve, 2nd, All in Favor.

B. Drugs for Asthma and COPD Literature Scan (pages 10-42)
   1. Update the LAMA/LABA PA criteria to accommodate Trelegy Ellipta based on evidence.
   2. Remove the coverage of uncomplicated chronic bronchitis from the ICS, LABA, LABA/ICS and LAMA/LABA PA criteria as this is no longer a funded diagnosis.

**ACTION:** Motion to approve, 2nd, All in Favor of number 1. Majority in favor, one opposed to number two. Approved.

### III. DUR New Business

A. Hepatitis C Direct-Acting Antivirals Policy Discussions (pages 43-54)
   Dr. Herink presented the proposal of modifying the PA criteria.
   1. Prior authorization criteria
      i. Modify PA criteria to clarify the definition of type 2 diabetes and insulin resistance.
   2. Treatment of Hepatitis C in people who inject drugs presentation. Presented by Dr. Seaman, OHSU
   3. Public Comment
   4. Discussion of clinical recommendations to OHA

**ACTION:** Modified proposed language in 8e to just type 2 diabetes mellitus and remove proposed insulin resistance definition. Requested staff bring back SUD question with evidence to September P&T meeting. Motion to approve, 2nd. Majority in favor, two opposed. Approved.
IV. Preferred Drug List New Business

A. Biologics for Autoimmune conditions class update (pages 55 - 74)
   Dr. Page presented the proposal of updating the PA criteria to:
   
   1. Modify PA Criteria as follows:
      a. Add new and updated indications to the approved indications table
      b. Add guselkumab and sarilumab to the PA criteria
      c. Remove natalizumab (Tysabri) from biologic PA criteria

   ACTION: Recommended changing the table heading in PA criteria to approved and funded conditions. Motion to approve, 2nd. All in favor. Approved.

B. Vesicular Monoamine Transporter 2 Inhibitors Class Review (pages 108-134)
   Dr. Sentena presented the proposal to update the PA criteria to:
   
   1. Create a new PDL class for VMAT2 inhibitors.
   2. Implement prior authorization criteria for valbenazine, deutetabenazine and tetrabenazine to ensure appropriate use.
   3. Due to limited efficacy and safety data, make all products non-preferred.

   ACTION: Modify PA to remove question #10 concerning specific diagnoses. Motion to approve, 2nd. All in favor. Approved.

C. Oral First and Second Generation Antipsychotics Class Update (pages 135-162)

D. ACTION: Deferred to the March meeting

E. PCSK-9 Inhibitors Class Update (pages 163-184)
   Dr. Herink presented the class update
   
   1. Continue to require prior authorization for approval of evolocumab and alirocumab to approve for high CV risk patients that have been included in clinical studies.
   2. No changes to PDL recommended.

   ACTION: Modify PA requirement for trial of high-intensity statin and ezetimibe to 3 months in question #4 and remove time restriction for a recent LDL-C. Modify definition for clinical atherosclerotic cardiovascular disease in question #3 to mirror inclusion criteria of clinical trials and require at least one additional major risk factor or 2 minor risk factors. Motion to approve, 2nd. All in favor. Approved.

V. DUR Activities

A. Quarterly Utilization Reports (pages 185-190)
B. ProDUR Report (pages 191-194)
C. RetroDUR Report (pages 195-198)

ACTION: Deferred to the March meeting
VI. EXECUTIVE SESSION

VII. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session

A. Drugs for Ashtma and COPD Literature Scan (pages 10-42)
   *
   **ACTION:** No changes to the PMPDP
   
   Motion, 2nd, All in Favor. Approved.

B. Biologics for Autoimmune conditions class update (pages 55 - 74)
   *
   **ACTION:** Modify PA criteria to require trial and failure of preferred Humira or Enbrel products.
   
   Motion, 2nd, All in Favor. Approved.

C. Vesicular Monoamine Transporter 2 Inhibitors Class Review (pages 108-134)
   *
   **ACTION:** No changes to the PMPDP. Refer to HERC for prioritization consideration and update PA criteria as needed.
   
   Motion, 2nd, All in Favor. Approved.

D. PCSK-9 Inhibitors Class Update (pages 163-184)
   *
   **ACTION:** No changes to the PMPDP.
   
   Motion, 2nd, All in Favor. Approved.

VIII. ADJOURN